普罗西亚尼丁A2是一种多醇自增强剂,通过多方面的胰岛素相关机制改善高血糖
Bo-Rim Song1, Sung Kyu Yoon1, Chang Hyung Lee2,3
1Department of Food Science and Biotechnology, Kyungpook National University, 80, Daehak-ro, Buk-gu, Daegu, 41566, Korea.
Scientific reports
|November 21, 2025
概括
普罗基亚尼丁A2 (PCA2),一种天然的黄类化合物,通过抑制α-葡萄糖酶和增强葡萄糖吸收,有效降低血糖. 这种化合物对旨在管理糖尿病和代谢障碍的功能性食品有希望.
科学领域:
- 生物化学 生物化学
- 药理学 药理学是指药理学的学科.
- 营养保健品 营养保健品
背景情况:
- 在果中发现的一种黄类物质普罗基亚尼丁A2 (PCA2) 具有生物活性,但其抗糖尿病作用尚不清楚.
- 现有研究强调了PCA2的潜力,需要对其降糖机制进行进一步的研究.
研究的目的:
- 通过计算,细胞和动物模型评估Procyanidin A2 (PCA2) 的抗糖尿病潜力.
- 阐明PCA2降血糖效应背后的分子机制.
主要方法:
- 在分子对抗α-葡萄糖酶的对接 (PDB: 3TOP).
- 在体外测试中使用C2C12和INS-1细胞来评估毒性,葡萄糖吸收和蛋白质表达 (AMPK,AKT,GLUT4,自标志物).
- 在糖尿病小鼠的体内研究包括葡萄糖耐受性测试,组织学分析 (H&E,PAS) 和西式斑点.
主要成果:
- PCA2表现出对α-葡萄糖酶的竞争性抑制 (IC50 = 3.62 μM) 并对100 μM的细胞无毒.
- 通过AMPK/AKT通路和GLUT4转位,PCA2增强了葡萄糖的吸收,减少了氧化应激,并调节了自蛋白 (Beclin1,LC3-II,Atg5,p62).
- 在糖尿病小鼠中,PCA2改善了葡萄糖耐受性,保存了胰腺β细胞,并使糖原水平正常化,有分子证据支持胰岛素信号传递和自调节.
结论:
- 普罗亚尼丁A2通过多种机制显示出显著的降血糖效应,包括酶抑制和改善胰岛素敏感性.
- PCA2显示出作为一种功能性食品成分的潜力,用于管理高血糖和代谢功能障碍.
- 对PCA2的进一步研究可能会导致糖尿病管理的新型治疗策略.
相关概念视频
Dipeptidyl Peptidase 4 Inhibitors
566
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
566
Oral Hypoglycemic Agents: Biguanides and Glitazones
567
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
567
Glucagon-like Receptor Agonists
824
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
824
Hormones Regulating Blood Glucose
6.4K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
6.4K
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
2.1K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
Insulin and C-peptide are...
2.1K
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
509
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
509

